Detalle Publicación

ARTÍCULO
Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain
Autores: Moya-Alarcon, C.; Gonzalez-Dominguez, A. (Autor de correspondencia); Simon, S. ; Perez-Roman, I. ; González Martín, Antonio; Bayo-Lozano, E.; Sanchez-Heras, A. B.
Título de la revista: CLINICAL AND TRANSLATIONAL ONCOLOGY
ISSN: 1699-048X
Volumen: 21
Número: 8
Páginas: 1076 - 1084
Fecha de publicación: 2019
Lugar: WOS
Resumen:
PurposeGermline mutations in BRCA1 and/or BRCA2 genes (gBRCA1/2m) are associated with an increased risk of breast cancer (BC) and ovarian cancer (OC). The aim of this study was to estimate the efficiency of providing germline BRCA1/2 testing to high-grade epithelial ovarian cancer (HGEOC) patients without family history of OC or BC and the subsequent testing and management of their relatives with gBRCA1/2m in Spain.Methods/patientsIncident HGEOC patients without family history of OC or BC who were gBRCA1/2m carriers and their relatives were simulated in a 50-year time horizon. The study compared two scenarios: BRCA1/2 testing vs no testing, using the perspective of the Spanish National Health Service. Cancer risk among gBRCA1/2m carriers was estimated based on their age and whether they had undergone risk-reducing surgeries. Direct healthcare costs and utilities of patients who developed EOC and BC were also included. A probabilistic sensitivity analysis (PSA) with 5 thousand simulations was developed considering25% of the base-case value.ResultsThe BRCA1/2-testing scenario amounted to Euro13,437,897.43 while the no-testing scenario amounted to Euro12,053,291.17. It was estimated that the screening test improved the quality of life among the patients' relatives by 43.8 quality-adjusted life years (QALYs). The incremental cost-utility ratio (ICUR) was Euro31,621.33/QALY in the base case. The PSA showed that 89.12% of the simulations were below the Euro50,000/QALY threshold.Conclusion Providing this screening test to HGEOC patients and their relatives is cost-effective and it allows one to identify a target population with high risk of cancer to provide effective prevention strategies.